Jelena Klawitter
Concepts (535)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 15 | 2025 | 244 | 4.290 |
Why?
| | Metabolomics | 21 | 2025 | 737 | 2.860 |
Why?
| | Kidney | 21 | 2025 | 1491 | 2.570 |
Why?
| | Tandem Mass Spectrometry | 17 | 2026 | 574 | 2.550 |
Why?
| | Cardiopulmonary Bypass | 10 | 2025 | 217 | 2.120 |
Why?
| | Immunosuppressive Agents | 15 | 2019 | 824 | 1.780 |
Why?
| | Chromatography, High Pressure Liquid | 14 | 2024 | 588 | 1.730 |
Why?
| | Oxidative Stress | 18 | 2020 | 1367 | 1.590 |
Why?
| | Cyclosporine | 10 | 2019 | 256 | 1.580 |
Why?
| | Metabolome | 9 | 2025 | 390 | 1.280 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2017 | 438 | 1.170 |
Why?
| | Sirolimus | 9 | 2019 | 282 | 1.080 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 1.010 |
Why?
| | Kidney Transplantation | 11 | 2025 | 702 | 1.000 |
Why?
| | Cardiac Surgical Procedures | 3 | 2022 | 608 | 0.990 |
Why?
| | Biomarkers | 23 | 2025 | 4329 | 0.940 |
Why?
| | Energy Metabolism | 8 | 2022 | 930 | 0.880 |
Why?
| | Pravastatin | 4 | 2025 | 45 | 0.880 |
Why?
| | Proteomics | 14 | 2020 | 1202 | 0.870 |
Why?
| | Acute Kidney Injury | 3 | 2022 | 861 | 0.860 |
Why?
| | Allografts | 1 | 2025 | 148 | 0.850 |
Why?
| | Tryptophan | 5 | 2024 | 183 | 0.830 |
Why?
| | Tacrolimus | 5 | 2025 | 192 | 0.740 |
Why?
| | TRPP Cation Channels | 2 | 2024 | 76 | 0.730 |
Why?
| | Endocannabinoids | 4 | 2025 | 55 | 0.730 |
Why?
| | Kynurenine | 5 | 2024 | 114 | 0.720 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2025 | 448 | 0.710 |
Why?
| | Endothelium, Vascular | 5 | 2021 | 952 | 0.710 |
Why?
| | Lovastatin | 2 | 2013 | 37 | 0.700 |
Why?
| | Adaptation, Physiological | 1 | 2025 | 567 | 0.670 |
Why?
| | Arginine | 2 | 2024 | 263 | 0.650 |
Why?
| | Menopause | 3 | 2020 | 327 | 0.650 |
Why?
| | Cannabinoids | 3 | 2024 | 181 | 0.630 |
Why?
| | Mass Spectrometry | 10 | 2021 | 728 | 0.620 |
Why?
| | Glomerular Filtration Rate | 11 | 2025 | 743 | 0.620 |
Why?
| | Heart Defects, Congenital | 5 | 2025 | 920 | 0.610 |
Why?
| | Kidney Failure, Chronic | 2 | 2025 | 582 | 0.600 |
Why?
| | Myocardium | 2 | 2017 | 948 | 0.590 |
Why?
| | Adenosine | 3 | 2018 | 255 | 0.570 |
Why?
| | Coronary Care Units | 1 | 2018 | 27 | 0.560 |
Why?
| | Signal Transduction | 11 | 2021 | 5234 | 0.560 |
Why?
| | Piperazines | 3 | 2009 | 367 | 0.560 |
Why?
| | Pyrimidines | 4 | 2014 | 530 | 0.530 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 36 | 0.520 |
Why?
| | Urine | 1 | 2017 | 63 | 0.510 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 32 | 0.500 |
Why?
| | Alkaline Phosphatase | 2 | 2018 | 144 | 0.490 |
Why?
| | Mycophenolic Acid | 3 | 2014 | 117 | 0.480 |
Why?
| | Male | 54 | 2026 | 73014 | 0.480 |
Why?
| | Length of Stay | 4 | 2025 | 1342 | 0.470 |
Why?
| | Chromatography, Liquid | 9 | 2026 | 452 | 0.460 |
Why?
| | Plasma | 1 | 2017 | 222 | 0.460 |
Why?
| | Disease Models, Animal | 9 | 2024 | 4565 | 0.460 |
Why?
| | Animals | 42 | 2024 | 38030 | 0.460 |
Why?
| | Adenosine Monophosphate | 1 | 2016 | 87 | 0.450 |
Why?
| | Female | 52 | 2026 | 79080 | 0.450 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 295 | 0.440 |
Why?
| | Isoprostanes | 3 | 2012 | 15 | 0.440 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 306 | 0.440 |
Why?
| | Humans | 75 | 2026 | 145625 | 0.440 |
Why?
| | Disease Progression | 8 | 2025 | 2857 | 0.420 |
Why?
| | Limit of Detection | 7 | 2024 | 92 | 0.410 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 6 | 0.410 |
Why?
| | Endothelium | 1 | 2014 | 119 | 0.410 |
Why?
| | Kidney Diseases | 4 | 2021 | 427 | 0.400 |
Why?
| | Dronabinol | 3 | 2026 | 250 | 0.400 |
Why?
| | Cell Proliferation | 4 | 2024 | 2497 | 0.400 |
Why?
| | Oxylipins | 2 | 2025 | 47 | 0.390 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 128 | 0.390 |
Why?
| | Inflammation | 9 | 2025 | 2915 | 0.380 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.370 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.370 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 82 | 0.360 |
Why?
| | Proteome | 3 | 2016 | 520 | 0.360 |
Why?
| | Oncogene Proteins | 1 | 2012 | 61 | 0.360 |
Why?
| | Dinoprost | 5 | 2019 | 51 | 0.360 |
Why?
| | Mutation | 2 | 2022 | 4082 | 0.350 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 845 | 0.350 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 262 | 0.340 |
Why?
| | Plant Extracts | 2 | 2024 | 191 | 0.340 |
Why?
| | Rats | 16 | 2024 | 5574 | 0.340 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 166 | 0.330 |
Why?
| | Nitric Oxide | 4 | 2024 | 883 | 0.330 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 286 | 0.320 |
Why?
| | Mitochondria | 1 | 2017 | 996 | 0.320 |
Why?
| | Purines | 2 | 2022 | 188 | 0.320 |
Why?
| | Postoperative Complications | 3 | 2021 | 2962 | 0.310 |
Why?
| | Blotting, Western | 6 | 2012 | 1176 | 0.310 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 627 | 0.310 |
Why?
| | Hypoxia | 6 | 2024 | 1209 | 0.300 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 456 | 0.300 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 357 | 0.290 |
Why?
| | Mice, Inbred C57BL | 12 | 2023 | 6021 | 0.290 |
Why?
| | Prostaglandins | 3 | 2022 | 94 | 0.290 |
Why?
| | Ureteral Obstruction | 2 | 2021 | 62 | 0.290 |
Why?
| | Theophylline | 2 | 2020 | 41 | 0.290 |
Why?
| | Autophagy | 3 | 2024 | 290 | 0.290 |
Why?
| | Glycolysis | 4 | 2012 | 341 | 0.280 |
Why?
| | Mice | 19 | 2024 | 18266 | 0.280 |
Why?
| | Antineoplastic Agents | 3 | 2009 | 2218 | 0.280 |
Why?
| | Arachidonate 12-Lipoxygenase | 2 | 2021 | 16 | 0.280 |
Why?
| | Infant | 10 | 2025 | 10093 | 0.280 |
Why?
| | Arachidonate 15-Lipoxygenase | 2 | 2021 | 20 | 0.270 |
Why?
| | Mice, Knockout | 7 | 2023 | 3121 | 0.270 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3538 | 0.260 |
Why?
| | Vascular Diseases | 2 | 2021 | 251 | 0.260 |
Why?
| | Case-Control Studies | 7 | 2024 | 3633 | 0.260 |
Why?
| | Amino Acids | 2 | 2025 | 513 | 0.260 |
Why?
| | Blood Vessels | 2 | 2019 | 164 | 0.260 |
Why?
| | Prospective Studies | 13 | 2025 | 8087 | 0.250 |
Why?
| | Reproducibility of Results | 11 | 2024 | 3396 | 0.250 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2009 | 889 | 0.250 |
Why?
| | Time Factors | 8 | 2022 | 7079 | 0.240 |
Why?
| | Infant, Newborn | 8 | 2025 | 6449 | 0.240 |
Why?
| | Rats, Wistar | 6 | 2018 | 449 | 0.230 |
Why?
| | Microsomes, Liver | 2 | 2019 | 85 | 0.230 |
Why?
| | Deoxyglucose | 2 | 2024 | 51 | 0.220 |
Why?
| | Child | 10 | 2025 | 22638 | 0.220 |
Why?
| | Swine | 3 | 2022 | 821 | 0.220 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 73 | 0.220 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.220 |
Why?
| | Breast Neoplasms | 3 | 2017 | 2411 | 0.220 |
Why?
| | Alkaloids | 1 | 2024 | 28 | 0.210 |
Why?
| | Treatment Outcome | 9 | 2025 | 11744 | 0.210 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2015 | 68 | 0.210 |
Why?
| | Mitragyna | 1 | 2024 | 8 | 0.210 |
Why?
| | Young Adult | 12 | 2023 | 14240 | 0.210 |
Why?
| | Transplantation, Homologous | 1 | 2025 | 415 | 0.210 |
Why?
| | Adult | 19 | 2026 | 40821 | 0.210 |
Why?
| | Adolescent | 10 | 2025 | 22451 | 0.210 |
Why?
| | Glycerides | 1 | 2024 | 16 | 0.200 |
Why?
| | Arachidonic Acids | 1 | 2024 | 42 | 0.200 |
Why?
| | Citrulline | 1 | 2024 | 45 | 0.200 |
Why?
| | Graft Rejection | 4 | 2017 | 504 | 0.200 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 39 | 0.190 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 25 | 0.190 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 3 | 2012 | 109 | 0.190 |
Why?
| | Analgesia | 1 | 2024 | 105 | 0.190 |
Why?
| | Cytokines | 5 | 2025 | 2079 | 0.180 |
Why?
| | Tissue Distribution | 2 | 2014 | 334 | 0.180 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 1 | 2022 | 28 | 0.180 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 592 | 0.170 |
Why?
| | Inflammation Mediators | 2 | 2021 | 507 | 0.170 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.170 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.170 |
Why?
| | Aminophylline | 2 | 2020 | 12 | 0.170 |
Why?
| | Double-Blind Method | 6 | 2025 | 2064 | 0.170 |
Why?
| | Curcumin | 1 | 2021 | 29 | 0.170 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 290 | 0.170 |
Why?
| | Fetal Diseases | 1 | 2023 | 192 | 0.170 |
Why?
| | Middle Aged | 17 | 2025 | 36359 | 0.170 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 77 | 0.170 |
Why?
| | Vascular Stiffness | 3 | 2021 | 488 | 0.160 |
Why?
| | Indoles | 1 | 2025 | 509 | 0.160 |
Why?
| | Calcium Channels, T-Type | 1 | 2022 | 104 | 0.160 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 46 | 0.160 |
Why?
| | Hypothalamus | 2 | 2018 | 161 | 0.160 |
Why?
| | Databases, Genetic | 1 | 2022 | 239 | 0.160 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 123 | 0.160 |
Why?
| | Methionine | 1 | 2021 | 160 | 0.160 |
Why?
| | Niacinamide | 1 | 2021 | 103 | 0.160 |
Why?
| | Organ Size | 2 | 2025 | 463 | 0.160 |
Why?
| | Benzamides | 3 | 2009 | 226 | 0.160 |
Why?
| | Complement Activation | 3 | 2018 | 412 | 0.150 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2020 | 50 | 0.150 |
Why?
| | Vasodilation | 3 | 2018 | 519 | 0.150 |
Why?
| | Nephrectomy | 1 | 2021 | 169 | 0.150 |
Why?
| | Cannabidiol | 1 | 2022 | 142 | 0.150 |
Why?
| | Pain | 1 | 2025 | 787 | 0.150 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 96 | 0.150 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 18 | 0.150 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 69 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 83 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 28 | 0.150 |
Why?
| | Bone Marrow | 2 | 2017 | 308 | 0.140 |
Why?
| | Vitamin D | 2 | 2019 | 402 | 0.140 |
Why?
| | Spironolactone | 1 | 2019 | 40 | 0.140 |
Why?
| | Blood Proteins | 1 | 2020 | 239 | 0.140 |
Why?
| | Homocysteine | 1 | 2019 | 152 | 0.140 |
Why?
| | Glucose | 2 | 2017 | 1051 | 0.140 |
Why?
| | Brain | 2 | 2013 | 2981 | 0.140 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 334 | 0.140 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 69 | 0.140 |
Why?
| | Fontan Procedure | 1 | 2020 | 200 | 0.130 |
Why?
| | DNA Damage | 2 | 2019 | 437 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2018 | 265 | 0.130 |
Why?
| | Phenotype | 3 | 2022 | 3186 | 0.130 |
Why?
| | Group IV Phospholipases A2 | 1 | 2017 | 46 | 0.130 |
Why?
| | 5'-Nucleotidase | 1 | 2018 | 49 | 0.130 |
Why?
| | Therapies, Investigational | 1 | 2017 | 18 | 0.130 |
Why?
| | Metformin | 1 | 2021 | 328 | 0.130 |
Why?
| | Phenylpropionates | 1 | 2017 | 27 | 0.130 |
Why?
| | Cysteine | 1 | 2019 | 210 | 0.130 |
Why?
| | Complement Factor B | 1 | 2018 | 106 | 0.130 |
Why?
| | Terbutaline | 1 | 2017 | 7 | 0.130 |
Why?
| | Endothelins | 1 | 2017 | 61 | 0.130 |
Why?
| | Cell Cycle | 2 | 2011 | 595 | 0.130 |
Why?
| | Pyridazines | 1 | 2017 | 56 | 0.130 |
Why?
| | Sex Characteristics | 2 | 2013 | 798 | 0.130 |
Why?
| | Protein Kinases | 2 | 2017 | 311 | 0.130 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 129 | 0.130 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 91 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 133 | 0.130 |
Why?
| | Complement Factor H | 1 | 2018 | 81 | 0.130 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2018 | 195 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 767 | 0.120 |
Why?
| | Receptors, Calcitriol | 1 | 2017 | 54 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 169 | 0.120 |
Why?
| | Immunoglobulin M | 1 | 2018 | 284 | 0.120 |
Why?
| | Glutamic Acid | 1 | 2018 | 255 | 0.120 |
Why?
| | Brachial Artery | 4 | 2019 | 206 | 0.120 |
Why?
| | Calcineurin Inhibitors | 2 | 2014 | 67 | 0.120 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.120 |
Why?
| | Drug Synergism | 2 | 2014 | 353 | 0.120 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.120 |
Why?
| | Breast | 1 | 2017 | 154 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1184 | 0.120 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2013 | 88 | 0.120 |
Why?
| | Helminth Proteins | 1 | 2016 | 24 | 0.120 |
Why?
| | Extracellular Space | 1 | 2016 | 118 | 0.120 |
Why?
| | Solubility | 1 | 2016 | 240 | 0.120 |
Why?
| | Transplant Recipients | 1 | 2017 | 168 | 0.110 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 5 | 0.110 |
Why?
| | Linoleic Acids | 1 | 2015 | 6 | 0.110 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 35 | 0.110 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 41 | 0.110 |
Why?
| | Enzyme Activation | 1 | 2017 | 758 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2097 | 0.110 |
Why?
| | Therapeutic Equivalency | 2 | 2017 | 31 | 0.110 |
Why?
| | Premature Birth | 1 | 2019 | 389 | 0.110 |
Why?
| | Fishes | 1 | 2016 | 111 | 0.110 |
Why?
| | Aerosols | 1 | 2016 | 146 | 0.110 |
Why?
| | Postoperative Period | 1 | 2016 | 344 | 0.110 |
Why?
| | Chi-Square Distribution | 1 | 2016 | 511 | 0.110 |
Why?
| | Reperfusion Injury | 1 | 2018 | 300 | 0.110 |
Why?
| | Diet, Sodium-Restricted | 1 | 2015 | 39 | 0.110 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2019 | 437 | 0.110 |
Why?
| | Biological Availability | 2 | 2017 | 146 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2016 | 641 | 0.100 |
Why?
| | Serine | 1 | 2015 | 142 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 157 | 0.100 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.100 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 447 | 0.100 |
Why?
| | Macrophages, Alveolar | 2 | 2016 | 377 | 0.100 |
Why?
| | Tidal Volume | 1 | 2014 | 108 | 0.100 |
Why?
| | DNA Methylation | 1 | 2019 | 721 | 0.100 |
Why?
| | Child, Preschool | 3 | 2025 | 11888 | 0.100 |
Why?
| | Hospital Mortality | 1 | 2018 | 1037 | 0.100 |
Why?
| | Cattle | 1 | 2016 | 938 | 0.100 |
Why?
| | Cannabis | 1 | 2021 | 519 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 22 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2018 | 300 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 314 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2016 | 1293 | 0.100 |
Why?
| | Everolimus | 2 | 2012 | 112 | 0.100 |
Why?
| | Aging | 2 | 2015 | 1983 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 107 | 0.100 |
Why?
| | Respiration, Artificial | 2 | 2018 | 711 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | Reactive Oxygen Species | 3 | 2012 | 610 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2101 | 0.090 |
Why?
| | Cell Death | 2 | 2013 | 379 | 0.090 |
Why?
| | Lung | 3 | 2022 | 4119 | 0.090 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 58 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2455 | 0.090 |
Why?
| | Cytoprotection | 1 | 2012 | 55 | 0.090 |
Why?
| | Pilot Projects | 4 | 2023 | 1878 | 0.090 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 15 | 0.090 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 74 | 0.090 |
Why?
| | Ion Transport | 1 | 2012 | 61 | 0.090 |
Why?
| | K562 Cells | 2 | 2009 | 93 | 0.090 |
Why?
| | Gluconeogenesis | 1 | 2012 | 81 | 0.090 |
Why?
| | Nicorandil | 1 | 2012 | 11 | 0.090 |
Why?
| | Glutamine | 1 | 2012 | 110 | 0.090 |
Why?
| | Integrins | 1 | 2012 | 88 | 0.090 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 19 | 0.090 |
Why?
| | Fibronectins | 1 | 2012 | 136 | 0.090 |
Why?
| | Regression Analysis | 2 | 2012 | 994 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2910 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5875 | 0.090 |
Why?
| | Androgens | 1 | 2013 | 179 | 0.090 |
Why?
| | Phosphates | 1 | 2012 | 175 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 639 | 0.090 |
Why?
| | Glucuronides | 1 | 2011 | 18 | 0.090 |
Why?
| | Endothelial Cells | 2 | 2018 | 876 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.080 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.080 |
Why?
| | Administration, Oral | 3 | 2026 | 867 | 0.080 |
Why?
| | Cytoskeleton | 1 | 2012 | 180 | 0.080 |
Why?
| | Age Factors | 1 | 2018 | 3321 | 0.080 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2012 | 199 | 0.080 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 28 | 0.080 |
Why?
| | Models, Animal | 1 | 2013 | 386 | 0.080 |
Why?
| | Liver Transplantation | 1 | 2017 | 699 | 0.080 |
Why?
| | Fatty Acids | 1 | 2014 | 460 | 0.080 |
Why?
| | Lung Injury | 1 | 2014 | 262 | 0.080 |
Why?
| | Aged | 7 | 2025 | 26251 | 0.080 |
Why?
| | Artifacts | 1 | 2011 | 142 | 0.080 |
Why?
| | Cell Survival | 2 | 2012 | 1102 | 0.080 |
Why?
| | Serotonin | 2 | 2024 | 297 | 0.080 |
Why?
| | Citric Acid Cycle | 1 | 2010 | 58 | 0.080 |
Why?
| | Estrogens | 1 | 2013 | 364 | 0.080 |
Why?
| | Drugs, Generic | 1 | 2010 | 28 | 0.080 |
Why?
| | Cross Reactions | 1 | 2010 | 129 | 0.080 |
Why?
| | Flow Cytometry | 2 | 2014 | 1160 | 0.080 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2007 | 175 | 0.070 |
Why?
| | Proteinuria | 1 | 2010 | 103 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2013 | 362 | 0.070 |
Why?
| | Drug Approval | 1 | 2010 | 93 | 0.070 |
Why?
| | Reference Standards | 1 | 2009 | 176 | 0.070 |
Why?
| | Heart Ventricles | 2 | 2024 | 762 | 0.070 |
Why?
| | Cells, Cultured | 3 | 2013 | 4112 | 0.070 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 49 | 0.070 |
Why?
| | Risk Assessment | 1 | 2018 | 3678 | 0.070 |
Why?
| | Oncogenes | 1 | 2009 | 113 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1790 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1992 | 0.070 |
Why?
| | Lysosomes | 2 | 2021 | 133 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 544 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2012 | 320 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1717 | 0.070 |
Why?
| | Cross-Over Studies | 3 | 2017 | 612 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
| | Astrocytes | 1 | 2010 | 229 | 0.070 |
Why?
| | Phospholipids | 1 | 2009 | 215 | 0.070 |
Why?
| | Lactic Acid | 1 | 2009 | 295 | 0.070 |
Why?
| | Food Hypersensitivity | 1 | 2010 | 165 | 0.070 |
Why?
| | Apoptosis | 3 | 2012 | 2436 | 0.060 |
Why?
| | F2-Isoprostanes | 2 | 2018 | 21 | 0.060 |
Why?
| | Lipid Metabolism | 1 | 2011 | 533 | 0.060 |
Why?
| | Fibrosis | 2 | 2021 | 568 | 0.060 |
Why?
| | Intestinal Mucosa | 1 | 2012 | 666 | 0.060 |
Why?
| | Allergens | 1 | 2010 | 390 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2021 | 173 | 0.060 |
Why?
| | Nucleotides | 1 | 2007 | 128 | 0.060 |
Why?
| | Hypertension | 1 | 2015 | 1270 | 0.060 |
Why?
| | Hydroxylation | 2 | 2019 | 47 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1118 | 0.060 |
Why?
| | Estradiol | 2 | 2020 | 517 | 0.060 |
Why?
| | Pulse Wave Analysis | 2 | 2018 | 268 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 432 | 0.060 |
Why?
| | Indoleacetic Acids | 1 | 2025 | 10 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2206 | 0.060 |
Why?
| | Renal Circulation | 1 | 2025 | 75 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2024 | 454 | 0.050 |
Why?
| | Kynurenic Acid | 1 | 2024 | 18 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 1800 | 0.050 |
Why?
| | Isomerism | 1 | 2024 | 55 | 0.050 |
Why?
| | Blood Pressure | 3 | 2019 | 1761 | 0.050 |
Why?
| | Drug Monitoring | 1 | 2008 | 399 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1996 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10840 | 0.050 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 33 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3210 | 0.050 |
Why?
| | Palliative Care | 2 | 2024 | 1032 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 90 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1283 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2025 | 249 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 134 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3123 | 0.050 |
Why?
| | Morbidity | 1 | 2024 | 317 | 0.050 |
Why?
| | bcl-2-Associated X Protein | 2 | 2013 | 53 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 33 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 56 | 0.050 |
Why?
| | Androstanols | 1 | 2022 | 30 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 1034 | 0.050 |
Why?
| | Urinalysis | 2 | 2015 | 82 | 0.040 |
Why?
| | Drug Interactions | 2 | 2017 | 403 | 0.040 |
Why?
| | Steroids | 1 | 2022 | 160 | 0.040 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2021 | 34 | 0.040 |
Why?
| | Cell Line | 2 | 2021 | 2809 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 138 | 0.040 |
Why?
| | Nitriles | 1 | 2022 | 211 | 0.040 |
Why?
| | Pregnancy | 3 | 2019 | 7217 | 0.040 |
Why?
| | Rats, Inbred Lew | 2 | 2012 | 105 | 0.040 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 73 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 94 | 0.040 |
Why?
| | Drug Stability | 2 | 2011 | 168 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 89 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2021 | 62 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 162 | 0.040 |
Why?
| | Pharmacokinetics | 1 | 2020 | 33 | 0.040 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2020 | 25 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2022 | 221 | 0.040 |
Why?
| | Cohort Studies | 2 | 2023 | 6045 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 138 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 150 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 150 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2015 | 1244 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 301 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 14 | 0.040 |
Why?
| | Molecular Structure | 2 | 2014 | 483 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 82 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 58 | 0.040 |
Why?
| | Pulmonary Veins | 1 | 2020 | 110 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1271 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2019 | 93 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 163 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 175 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.030 |
Why?
| | Reference Values | 2 | 2013 | 787 | 0.030 |
Why?
| | Creatinine | 1 | 2020 | 511 | 0.030 |
Why?
| | Complement Membrane Attack Complex | 1 | 2018 | 38 | 0.030 |
Why?
| | Complement C5a | 1 | 2018 | 54 | 0.030 |
Why?
| | Rewarming | 1 | 2018 | 22 | 0.030 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2018 | 29 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2018 | 81 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2131 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 188 | 0.030 |
Why?
| | Position-Specific Scoring Matrices | 1 | 2017 | 2 | 0.030 |
Why?
| | Femoral Artery | 1 | 2018 | 183 | 0.030 |
Why?
| | Birth Weight | 1 | 2020 | 521 | 0.030 |
Why?
| | Carotid Arteries | 1 | 2018 | 206 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1754 | 0.030 |
Why?
| | Half-Life | 1 | 2017 | 157 | 0.030 |
Why?
| | Malates | 1 | 2016 | 8 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 312 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 1125 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 394 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 317 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 569 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1075 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 217 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 143 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 66 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 344 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 37 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 2018 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 622 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 479 | 0.030 |
Why?
| | Aldehydes | 1 | 2016 | 140 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 691 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 384 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 57 | 0.030 |
Why?
| | Safety | 1 | 2017 | 346 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 982 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 324 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 242 | 0.030 |
Why?
| | Larva | 1 | 2016 | 242 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 21 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 31 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 382 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 567 | 0.030 |
Why?
| | Kinetics | 1 | 2018 | 1553 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 85 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 319 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 66 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2017 | 887 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1531 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 58 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 97 | 0.030 |
Why?
| | Prognosis | 2 | 2013 | 4331 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 14 | 0.020 |
Why?
| | Binding Sites | 1 | 2017 | 1306 | 0.020 |
Why?
| | Macrophages | 1 | 2021 | 1530 | 0.020 |
Why?
| | Thiazoles | 1 | 2014 | 139 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 112 | 0.020 |
Why?
| | Dihydrotestosterone | 1 | 2013 | 40 | 0.020 |
Why?
| | Orchiectomy | 1 | 2013 | 72 | 0.020 |
Why?
| | Altitude | 1 | 2017 | 469 | 0.020 |
Why?
| | Cell Count | 1 | 2013 | 315 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2015 | 507 | 0.020 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2013 | 55 | 0.020 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2013 | 41 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2013 | 172 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 686 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 333 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 195 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 76 | 0.020 |
Why?
| | Streptozocin | 1 | 2012 | 22 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 192 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2013 | 149 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 174 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1824 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1114 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 240 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 200 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 613 | 0.020 |
Why?
| | Neuroprotective Agents | 1 | 2013 | 146 | 0.020 |
Why?
| | Transplantation | 1 | 2011 | 31 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 578 | 0.020 |
Why?
| | Podocytes | 1 | 2012 | 80 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1429 | 0.020 |
Why?
| | Drug-Eluting Stents | 1 | 2011 | 88 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 278 | 0.020 |
Why?
| | Methylation | 1 | 2011 | 241 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2239 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 721 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2012 | 198 | 0.020 |
Why?
| | Daucus carota | 1 | 2010 | 2 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 662 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 630 | 0.020 |
Why?
| | Buffers | 1 | 2010 | 56 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2010 | 24 | 0.020 |
Why?
| | Graft Survival | 1 | 2012 | 508 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 861 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 403 | 0.020 |
Why?
| | Hot Temperature | 1 | 2012 | 396 | 0.020 |
Why?
| | Antigens, Plant | 1 | 2010 | 55 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1758 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2010 | 382 | 0.020 |
Why?
| | Ribose | 1 | 2009 | 21 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 179 | 0.020 |
Why?
| | Plant Proteins | 1 | 2010 | 110 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2446 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1372 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 383 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 9 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 820 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 76 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 207 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 124 | 0.020 |
Why?
| | Vegetables | 1 | 2010 | 159 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2020 | 17291 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2009 | 143 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2533 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 899 | 0.020 |
Why?
| | Liver | 1 | 2016 | 1859 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 439 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 348 | 0.020 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 973 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2088 | 0.010 |
Why?
| | Genotype | 1 | 2011 | 1866 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2835 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2013 | 3005 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4588 | 0.010 |
Why?
| | Neurons | 1 | 2013 | 1663 | 0.010 |
Why?
| | Ischemia | 1 | 2007 | 421 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 2591 | 0.010 |
Why?
| | United States | 1 | 2010 | 16041 | 0.010 |
Why?
|
|
Klawitter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|